Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Glybera
Pharma
GSK's talk of selling out points up rare disease challenges
GlaxoSmithKline’s decision to explore a sale for its rare disease portfolio offers both an opportunity and a warning sign.
Eric Sagonowsky
Jul 27, 2017 10:36am
How will Novartis price CAR-T? Here are some clues
Jun 8, 2017 10:17am
BioMarin sees 'high end' pricing on Brineura
Apr 24, 2017 10:31am
UniQure gives up on $1M+ gene therapy Glybera
Apr 20, 2017 10:21am
The world's 10 most pricey meds, topped at $1.2M
Apr 19, 2017 11:02am
GSK inks money-back deal on $665K gene therapy Strimvelis
Aug 9, 2016 10:51am
